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Abstract
Background: Endocrine disrupting chemicals are widely distributed in the environment and derive from many different
human activities or can also be natural products synthesized by plants or microorganisms. The phytoestrogen, genistein (49,
5, 7-trihydroxy-isoflavone), is a naturally occurring compound found in soy products. Genistein has been the subject of
numerous studies because of its known estrogenic activity.
Methodology/Principal Findings: We report that genistein exposure of zebrafish embryos induces apoptosis, mainly in the
hindbrain and the anterior spinal cord. Timing experiments demonstrate that apoptosis is induced during a precise
developmental window. Since adding ICI 182,780, an ER antagonist, does not rescue the genistein-induced apoptosis and
since there is no synergistic effect between genistein and estradiol, we conclude that this apoptotic effect elicited by
genistein is estrogen-receptors independent. However, we show in vitro, that genistein binds and activates the three
zebrafish estrogen receptors ERa, ERb-A and ERb-B. Furthermore using transgenic ERE-Luciferase fish we show that
genistein is able to activate the estrogen pathway in vivo during larval stages. Finally we show that genistein is able to
induce ectopic expression of the aromatase-B gene in an ER-dependent manner in the anterior brain in pattern highly
similar to the one resulting from estrogen treatment at low concentration.
Conclusion/Significance: Taken together these results indicate that genistein acts through at least two different pathways
in zebrafish embryos: (i) it induces apoptosis in an ER-independent manner and (ii) it regulates aromatase-B expression in
the brain in an ER-dependent manner. Our results thus highlight the multiplicity of possible actions of phytoestrogens, such
as genistein. This suggests that the use of standardized endpoints to study the effect of a given compound, even when this
compound has well known targets, may carry the risk of overlooking interesting effects of this compound.
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Introduction
There is considerable concern over the environmental occur-
rence of endocrine-disrupting chemicals (EDCs), i.e., natural and
man-made substances that interfere with the endocrine system of
vertebrates [1,2,3]. These molecules have the potential to
modulate or disrupt the synthesis, secretion, transport, binding,
action, or elimination of endogenous hormones in the body and
consequently to affect homeostasis, development, reproduction,
and behavior in many organisms, including humans. EDCs are
now widely distributed in the environment and derive from many
different human activities (pesticides, industrial products, cancer
drugs, fattening agents) and are also found as natural products
(human and animal waste; phytoestrogens).
Genistein (49,5,7-trihydroxy-isoflavone) belongs to the isofla-
vone class of flavonoids and is classified as a phytoestrogen, i.e.,
plant-derived compounds that possess estrogen-like biological
activity (reviewed in [4,5,6]). Genistein, found in various soy
foods at concentrations of 1.9–229 mg/g, is the main component
of soy implicated in cancer chemoprevention [7] and is being
evaluated in preliminary trials for breast, prostate and uterus
cancers treatment [8,9], in osteoporosis [10], cardiovascular
diseases [11] and for treatment of menopausal symptoms [12].
Genistein is known to bind the human estrogen receptors (ERs)
and exhibits estrogenic activities [5,13,14,15]. The actions of
estrogens, antiestrogens, and phytoestrogens are mediated by two
different estrogen receptors, ERa and ERb whose expression
levels vary dramatically among different organs or cell types (see
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review in [16,17]). The two receptors regulate different sets of
biological functions and induce dissimilar responses within the
same cell type or tissue (reviewed in [16]). Interestingly, it has been
shown that genistein preferentially binds human ERb over the
human ERa: compared with ERa, ERb exhibits a 7–70-fold
greater binding affinity for genistein, whereas E2 (17b-estradiol)
binds ERa and ERb with equal affinity [13,18,19]. Recent
detailed comparison of isoflavones such as genistein and the
natural estrogen E2 suggest that their ERb selectivity involves a
capacity to induce an activation function-2 (AF-2) surface of ERb
that has greater affinity for coregulators such as glucocorticoid
interacting receptor protein 1 compared with ERa. ([20]; see
review in [21]). Therefore, it is now believed that phytoestrogens
like genistein, act as natural selective estrogen receptor
modulators (SERMs) that elicit distinct clinical effects from
estrogens by selectively recruiting coregulatory proteins to ERb
triggering specific transcriptional pathways ([20]; see a review on
selective agonists of nuclear receptor ligands in [22]). These
functional data have been fully confirmed and extended by
detailed structural analysis of human ERa and ERb complex
with genistein [23,24].
Given this known mode of action, genistein has been the subject
of numerous studies in experimental animals and humans because
of its possible beneficial and adverse health effects due to
estrogenic activity [21,25]. Recently, several other targets of
genistein have been identified suggesting that the mode of action of
this dietary compound is more complex than previously expected.
For example it has been suggested that genistein acting in the
micromolar range is able to bind to transthyretin and can have a
beneficial effect as an inhibitor of transthyretin amyloidosis [26].
One of the first described effects of genistein, which was published
over two decades ago, is the in vitro inhibition at the nanomolar
range of the tyrosine-specific protein kinase activity of the
epidermal growth factor (EGF) receptor pp60v-arc and pp110gag-
fes [27]. Moreover, genistein at 50 mM was shown to be an
inhibitor of cyclic AMP-phosphodiesterase (cAMP-PDE) activity
resulting in an increased cAMP accumulation [28]. Thus some of
the genistein targets have already been identified but its effects
during vertebrate embryonic development are still poorly defined.
In addition, the relative effects of these various pathways in vivo
remain to be determined.
Throughout the last decade, several fish species have been
considered as potential test organisms for evaluating the endocrine
disrupting properties of natural and synthetic chemicals in in vivo
test systems [29,30,31]. Since the first original description [32],
numerous reports have emphasized that the effluents of sewage
treatment plants induced sexual abnormalities, such as a high
incidence of intersex animals in various fish species [33].
Interestingly, recent studies have shown that isoflavone com-
pounds, including genistein, are discharged in water effluents and
are present in agricultural runoff as a result from intensive
livestock management. For instance, genistein was identified at a
concentration of 10 mg/L in the effluents from a pulp mill in
Ontario, Canada [34]. There have been relatively few studies on
the effects of genistein in teleosts fish and most of these studies
were focused on its estrogenic activity. Injections of genistein into
sturgeons (Acipenser baeri) induce vitellogenesis, a typical estrogenic
response in fish [35]. When genistein was intraperitonally injected
into the Japanese medaka (Oryzias latipes), the plasma E2 levels
were increased in exposed females and plasma testosterone levels
were reduced in exposed males [36]. In addition, exposure to
genistein at 1 mg/L causes gonadal intersex in male medakas as
well as delayed oocyte maturation, atretic oocytes and enlarged
ovarian lumen in the female [37]. Gametogenesis and reproduc-
tive efficiency were reduced in rainbow trout (Oncorhynchus mykiss)
exposed to genistein-enriched diets for one year [38].
All these studies were mainly focused on sexual abnormalities of
the treated fish, because of the known estrogen effects (and by
extension phytoestrogens such as genistein) in sex determination
and gonad differentiation. Strikingly, however, only very few
studies have looked at the developmental defects induced by
genistein exposure in fish.
The zebrafish (Danio rerio) has become one of the most popular
and well-established models in genetics and developmental biology
[39,40,41]. In addition the zebrafish is commonly used in
toxicology to study effects of pollutants such as endocrine
disruptors [42,43] and as a model organism in drug discovery
[44]. This model is valuable because of its high reproductive
capacity and the transparency of the embryos as well as its rapid
development that allow morphological observations of the
organogenesis after pharmacological treatments.
In the present study, we have studied the effects induced by
genistein exposure during zebrafish embryonic development. We
found that genistein treatment induces apoptosis mainly in the
hindbrain and in the anterior spinal cord in early zebrafish
embryos. We observed that this effect was not impaired in the
presence of the anti-estrogen ICI 182,780 suggesting that it is
induced through an ER-independent pathway. In contrast, we
found that genistein can indeed act through the estrogen receptors
both in vitro and in vivo. Using transgenic ERE-luciferase fish, we
demonstrate that genistein activates the estrogen pathway, in vivo.
Finally, we found that genistein is able to induce ectopic expression
of the aromatase-B gene in the brain in an ER-dependent manner.
We conclude that genistein has two separate effects in vivo during
zebrafish embryogenesis: (i) inducing early apoptosis in an ER-
independent manner and (ii) regulating specific gene expression in
an ER-dependent manner. Our results thus highlight the complex
in vivo effects that can be elicited by a single EDC molecule.
Results
Genistein induces apoptosis during zebrafish embryonic
development
In order to determine the phenotypic abnormalities induced by
genistein exposure during zebrafish embryonic development, we
treated zebrafish embryos at concentrations up to 17.5 mM, after
the mid-blastula transition when transcription of the zygotic
genome first occurs [45]. We observed that at high concentration
(17.5 mM) genistein induces a strong mortality. At this concentra-
tion, 90% of the embryos survive up to 96 hours post fertilization
(hpf), but mortality increases dramatically afterwards and only
35% are still alive at 105 hpf, the few remaining embryos dying
shortly after this time point. The survival curve (data not shown)
indicates that treatments at 10 mM genistein or below do not
induce death of the embryos prior to 105 hpf (larval development
was not monitored).
We observed that the dying embryos presented obvious areas of
dying cells located in the neural tube, posterior to the mid-
hindbrain boundary (MHB) (compare Figure 1A with bracket in
Figure 1B). The number of dying cells increases with the
concentration of genistein used (data not shown). To determine
if these cells were apoptotic, we stained genistein treated embryos
at 24 hpf with acridine orange that specifically marks the apoptotic
cells [46]. Few apoptotic cells are detected in control embryos at
the level of the MHB (arrowhead in Figure 1C) and in the dorsal
hindbrain (arrow in Figure 1C), whereas we found a lot more
apoptotic cells in genistein treated embryos (Figure 1D, E). We
observed that the number of acridine orange positive cells
Genistein Effects in Zebrafish
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increases in a dose-dependent manner when the embryos are
treated with genistein from 2.5 mM to 10 mM (compared
Figure 1D with 1E). The acridine orange staining confirms the
localization of apoptotic cells mainly in the hindbrain and the
anterior spinal cord (bracket in Figure 1E). Interestingly, we did
not detect apoptotic cells outside the central nervous system
(CNS).
We also treated zebrafish embryos with other isoflavones related
to genistein, namely genistin (the glycosylated form of genistein
found in soy products accounting to .65% of the isoflavone
content), apigenin (one of the citrus bioflavonoids) and daidzein
(found widely in plants particularly in soybeans). We found that
treatments of zebrafish embryos with 10 mM of these compounds
also induce apoptosis (Figure 1. F–H). Of note, daidzein exposure
induces apoptosis in a more anterior domain, mainly in the
forebrain and midbrain (Figure 1H), which contrasts with what is
observed when using the other compounds. Thus, it appears that a
large spectrum of isoflavonoids can induce apoptosis in early
zebrafish embryos. If we compare the efficiency of all of these
compound, we found that at 10 mM genistein exposure leads to a
maximal number of apoptotic cells, followed by daidzein and
genistin, respectively. Among the tested compounds apigenin is the
flavonoids that induces the fewest number of apoptotic cells.
We next confirmed the apoptotic status of the acridine orange
labelled cells using TUNEL assays, a direct method detecting the
presence of fragmented DNA [47]. Observation of fish labelled at
24 hpf by TUNEL assay confirms that genistein induces apoptosis
in a dose-dependent manner (see Figure S1 available in the web).
Moreover, using TUNEL assays that are more sensitive than
acridine orange staining we found that genistein induces apoptosis
at a concentration as low as 0.5 mM. A concentration of genistein
of 0.1 mM does not lead to a higher number of apoptotic cells than
in control embryos.
Altogether these results demonstrate that genistein exposure
induces significant cell death in the hindbrain and anterior spinal
cord during zebrafish embryonic development in a dose-
dependent manner. Interestingly, the effect is visible at relatively
low doses of genistein, since we detect increased TUNEL staining
at 24 hpf in embryos treated with 0.5 mM genistein.
Apoptosis is induced during early developmental stages
In order to shed light into the developmental stage at which
apoptosis can be detected in genistein treated embryos, we
performed time course experiments. We thus treated embryos
from 5 hpf onwards with 10 mM of genistein and we then detect
apoptotic cells using acridine orange staining at different
developmental time points. At 10 hpf (5 hours after the beginning
of the treatment) no acridine orange positive staining was detected
suggesting that at this time genistein does not yet induce apoptosis
at these developmental stages (Table 1). At 12 hpf (7 hours after
treatment), a few apoptotic cells were detected in control embryos
but this number was much higher after genistein treatment
(Table 1; Figure 2A and B). We observed the first apoptosis in
control embryos in the hindbrain. Interestingly, the region in
which genistein induced massive apoptosis, contains this area but
extends further posteriorly in the anterior spinal cord. At 15 hpf
the number of apoptotic cells in genistein treated embryos largely
increases (Table 1) and apoptosis is detected in almost the entire
CNS.
These experiments reveal that apoptosis is detected as early as
7 hours after genistein exposure. This suggests that genistein is
acting during a precise developmental window around 12 hpf. To
further substantiate the existence of such a precise window we thus
treated embryos with 2.5 mM of genistein at 5 hpf or 20 hpf and
monitored apoptosis 7 hours after exposure (Figure 2A–D). Except
in the lens and the epiphysis that are positive for acridine orange in
control embryos (Figure 2C arrow and arrowhead, respectively),
no apoptotic cells were observed on embryos treated at 20 hpf,
while strong apoptosis is detected 7 hours after exposure on fish
treated from 5 hpf onwards (compare Figure 2B and 2D). No
Figure 1. Genistein induces apoptosis during zebrafish development (A) 24 hpf photo of an untreated embryo and an embryo
treated with 10 mM of genistein showing necrosis in the posterior hindbrain and in the anterior spinal cord marked by the white
bracket (B). (C–H) Apoptotic cell detection at 24 hpf using acridine orange. (C) Control embryo with few apoptotic cells in the midbrain (arrowhead)
and the hindbrain (arrow). (D, E) Embryo exposed to 2.5 and 10 mM of genistein showing an increased number of stained cells especially in the
hindbrain and a high number of apoptotic cells in the hindbrain and anterior spinal cord when high concentrations of genistein are used (bracket in
F). (F–H) Apoptosis mainly found in the hindbrain (arrows) induced by compounds related to genistein: genistin (F), apigenin (G) and daidzein (H)
each at 10 mM. Using daidzein, numerous apoptotic cells are detected in the forebrain in comparison to what is observed with the other compounds.
doi:10.1371/journal.pone.0004935.g001
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apoptotic cells were observed later during embryonic development
on embryos treated at 20 hpf (data not shown). This suggests that
there is effectively a specific early developmental window of
genistein sensitivity, during which exposure induces apoptosis.
Therefore, we decided to define more precisely the length of this
developmental window by treating zebrafish embryos at different
time points and assaying for apoptosis at 27 hpf (Figure 2E–F). In
this experimental setup, we observed that apoptosis could be
observed in embryos treated up to 10 hpf (Figure 2E, bracket),
whereas no apoptosis is detected when treatment starts at 12.5 hpf
(Figure 2F) or later (data not shown). This confirms the idea that
genistein acts during a precise developmental window up to the
beginning of somitogenesis.
Altogether these experiments suggest that genistein induces
apoptosis during the end of gastrulation or in the early
somitogenesis stages. Moreover, even if genistein induces effects
that can still be detected at late developmental stages (up to
48 hpf), the exposure must start prior to 12.5 hpf to be effective.
The genistein-induced apoptosis is ER-independent
Genistein is a well-known estrogen receptor agonist (see [16] for
a review). We thus tested whether E2, the natural ligand of
estrogen receptors, was able to induce a similar effect as genistein.
Given that estradiol binds and activates the zebrafish ERs with
affinities in the nanomolar range [48,49], we treated embryos at
5 hpf with up to 1 mM of E2 (Figure 3B) and assayed the induced
apoptosis with acridine orange staining at 28 hpf. As in the control
(Figure 3A), very few acridine orange positive cells are detected
suggesting that exogenous E2 does not induce apoptosis in early
zebrafish embryos (Figure 3B). Figure S2 shows the quantitative
analysis of these results after counting the number of apoptotic
cells in embryos stained with acridine orange, using 40 embryos
per point.
This result suggests that the apoptosis induced by genistein
exposure may not be mediated through the estrogen signaling
pathway. To test if a link exists between genistein-induced
apoptosis and estrogen signaling we co-treated embryos with
genistein and with ICI 182,780, a classical estrogen receptor
antagonist [50]. ICI treatment alone induces apoptosis at
concentration of 1 mM (Figure 3C), an effect seen in numerous
studies using different model systems [51]. This apoptosis induced
by ICI is effectively E2 dependant since it is reverted by co-
treatment of ICI and E2. Indeed, as shown in Figure S2, lower
panel cotreatments with E2 and ICI at a 1:1 ratio very severely
shut down the apoptotic effect induced by ICI. As shown above,
genistein induces a strong apoptotic effect (Figure 3D; see Figure
Figure 2. Genistein-induced apoptosis is developmental stage-dependent. Embryos were treated with 2.5 mM genistein for 7 hours starting
at 5 hpf (B) or 20 hpf (D) and stained with acridine orange. A high number of apoptotic cells, compare with control (A), are detected in embryos
treated from 5 hpf onwards. A similar localization (retina and epiphysis, arrow and arrowhead, respectively) and small number of apoptotic cells are
detected in control (C) and genistein-treated embryos from 20 hpf onwards (D). (E) Treatment from 10 hpf onwards induces a strong apoptosis
detected at 27 hpf (arrows), while a similar treatment started at 12.5 hpf did not induce apoptosis at 27 hpf (F).
doi:10.1371/journal.pone.0004935.g002
Table 1. Timing of the presence of apoptotic cells after
2.5 mM genistein treatment.
Time of Control Genistein 2.5 mM
10 hpf No apoptotic cells No apoptotic cells
12 hpf Presence of few apoptotic cells
in the brain
Presence of more apoptotic cells
than in control (brain and spinal
cord)
15 hpf Presence of few apoptotic cells Presence of a high number of
apoptotic cells
doi:10.1371/journal.pone.0004935.t001
Genistein Effects in Zebrafish
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S2 for quantitative data and statistical significance) at a
concentration higher than ICI (5 mM for Genistein vs 1 mM for
ICI). A full dose of genistein (5 mM) combined with a full dose of
E2 (1 mM) or a full dose of ICI 182,780 (1 mM) lead to a result
similar to that of genistein treatment alone with no statistically
different number of apoptotic cells present in each fish (Compare
Figure 3D with 3E and 3F). These results lead to two conclusions:
(i) genistein induces apoptosis in an ER independent manner as
cotreatment with estrogen receptor agonist or an antagonist does
not have any effect on the apoptosis induced by genistein; (ii)
genistein does not synergise with ICI in terms of inducing
apoptosis as the same number of apoptotic cells is observed with a
genistein exposure alone or in combination with ICI 182,780 (see
Discussion).
To better test if genistein has a synergistic effect with the
estrogenic pathway we then co-treated embryos with half a dose of
genistein (2.5 mM) and half a dose of E2 or ICI (0.5 mM). Again,
we did not observe any synergistic effect between ICI and genistein
comparable to a full dose of genistein (compare Figure 3D and 3H;
see also Figure S2). As a control, a half dose of E2 and ICI showed
as expected a very low number of apoptotic cells (Figure 3I). Of
note treatment of zebrafish embryos with half-dose (2.5 mM)
genistein and a full dose (1 mM) of ICI, in order to increase the
ICI/Genistein ratio do not induce a significant effect on the
genistein-induced apoptosis (not shown). We verified that the ICI
compound we used is a potent zebrafish ER-antagonist both in vivo
and in vitro (Table 2, see below). To check that the results we
obtained were not specific of the type of antagonist used we also
treated fish with tamoxifen (Figure S2). We observed that at 1 mM
tamoxifen induce a modest increase in the number of apoptotic
cells but that, as with ICI, co-treatement by genistein and
tamoxifen does not alter, positively or negatively, the effect of
genistein.
Taken together our results demonstrate that the action of
genistein for apoptosis induction is estrogen-receptor independent.
Genistein binds to and activates the three zebrafish ERs
The previous observation of a clear estrogen independent effect
of genistein during zebrafish embryonic development led us to test
if genistein is effectively able to induce an estrogenic response in
zebrafish embryos.
The zebrafish genome contains three ERs: ERa, ERb-A and
ERb-B ([48,49]; see [52] for nomenclature and complete
expression patterns). To test if genistein effectively binds to the
Figure 3. Genistein-induced apoptosis is estrogen receptor independent. (A,B) estradiol does not induce apoptosis. Embryos treated with
1 mM of E2 from 5 hpf onwards display the same pattern of apoptosis (retina and epiphysis) as controls (compare A and B). In contrast embryos
treated with 1 mM ICI 182,780 exhibit an increased number of apoptotic cells in the hindbrain (C). Genistein induce an apoptosis at 5 mM as shown
Figure 1 (D) and cotreatments with E2 (E) or ICI 182,780 (F) does not modify this effet. Effects of treatments with half dose (0.5 mM for E2 and ICI
182,780 and 2.5 mM for genistein) led to the same conclusions. See Supplementary Figure 2 for the quantitative analysis of these results.
doi:10.1371/journal.pone.0004935.g003
Table 2. Genistein elicit a transcriptional response in vivo
using ERE reporter fish. Three independent experiments were
performed.
Ligands Fold induction
Ethanol none
1 mM E2 X 655+/250
2.5 mM Genistein X 215+/220
1 mM ICI none
1 mM E2+10 mM ICI none
2.5 mM Genistein+1 mM ICI none
doi:10.1371/journal.pone.0004935.t002
Genistein Effects in Zebrafish
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zebrafish ERs, we used a limited proteolysis assay, which is a
widely used method that allows testing whether a given ligand
induces a conformational change of the receptor [53]. As seen in
Figure 4, the three zebrafish estrogen receptor proteins are
protected against trypsin degradation by E2 in a dose-dependent
manner. We observed a faint protection starting at 1 mM of E2
(lane 5) for ERa, 0.01 mM of E2 (lane 3) for ERb-A and 1 mM of
E2 (lane 5) for ERb-B and a plateau at 10 mM (lane 6), which is
similar for all receptors. Thus, in this assay, ERb-A appears to
bind E2 at lower concentrations than ERa and ERb-B. When we
used genistein, we observed that all receptors are protected against
trypsin degradation and that the protection starts at 10 mM (lane
6) for ERa and ERb-A and 100 mM (lane 7) for ERb-B. We
therefore conclude that genistein is able to bind to all three
zebrafish estrogen receptors with a comparable range of affinity.
Even though limited proteolysis assay cannot be used to define a
Kd value it seems clear from these experiments that the affinity of
the three zebrafish ERs for their natural ligand E2 is much higher
than it is for genistein. This clearly validates the range of
concentration used previously (see Figure 3) to measure the
combined effect of genistein and E2 on apoptosis.
Similarly, we observed that genistein is able to elicit a
transcriptional activation of the ERs in transient transfection assays
in Hela cells, which do not have endogenous estrogen receptors.
These cells were transiently transfected with a luciferase reporter
gene under the control of a classical ERE element (ERE-b Globin-
Luc), together with expression vectors encoding the zebrafish
estrogen receptors genes ERa, ERb-A and ERb-B. E2 induces a
clear activation of zebrafish ERs starting at 10210 M for ERb-A and
561029 M for ERa and ERb-A (Figure 5C) in accordance with
previously published data [48,49]. Genistein has similar effects on
the three receptors with a very faint activation detectable at 1028 M
and a maximal effect at 1026 (Figure 5D). In contrast, we observed
that, as previously published on human ERs, genistein has a clear
selectivity in favor of ERb since ERb is activated at a 10 fold lower
concentration (1029 M) than ERa (1028 M) (compare Figure 5B
with D) [13,18,19,23,54]. Taken together our results clearly
demonstrate that in vitro genistein has the capacity to bind and
activate all zebrafish ERs in a comparable manner.
In humans, the structural basis of the selectivity of genistein for
ERb versus ERa has been linked to two critical positions in the
ligand binding pocket, Met 336 and Ile 373, which are replaced by
a Leu and a Met respectively in ERa ([23]; see Figure 6A). In the
zebrafish ERs, we observed that all ERs have a leucine residue at
the position homologous to Met 336 in the human ERb meaning
that all zebrafish ERs are ‘‘ERa-like’’ for this residue. For the
other position (Ile 373 in ERb), the two zebrafish ERbs have an Ile
like human ERb, while the unique ERa has a Met, like its human
ERa ortholog. All together these results show that one of the two
crucial amino acids directly involved in the binding of genistein to
ER in all zebrafish sequences has a signature of an ERa type.
Exactly the same situation is found, when analyzing the sequences
of ERs from another fish model, the medaka Oryzias latipes. To
visualize the impact of these substitutions in the fish ERs we
performed a 3D modeling analysis of the ligand binding domains
from zebrafish ERs (Figure 6B). As expected after primary
structure analysis, the residues lining the ligand binding pocket
of human ERs and zebrafish ERs are very conserved with the few
pointed exceptions and are organized in a similar 3D configura-
tion. However, the slight change observed in Met 389 positioning
in zebrafish ERa, and the substitution of Met 336 in human ERb
by a Leu residue in zebrafish ERb (at position 354 and 369 in
zebrafish ERb-A and zebrafish ERb-B respectively), are likely to
equalize the relative affinity of genistein for zebrafish ERs. Taken
together these data suggest that the lack of selectivity of genistein
activation of zebrafish ERs may be explained by these specific
amino acid substitutions and slight change in the relative
positioning of certain residues.
Genistein elicits an estrogenic response in vivo
To demonstrate that genistein can elicit a transcriptional
response in vivo we used a transgenic reporter zebrafish line that
contains a luciferase gene under the control of an ERE linked to a
minimal promoter (36ERE-TATA-Luc) [55,56]. We performed
this assay in juvenile fishes (3 months old) since, in our hands, E2
does not induce a detectable luciferase response using these
transgenic fishes at embryonic stages (data not shown). The
transgenic ERE-Luc fish were treated with genistein at 2,5 mM in
Figure 4. Genistein binds the three zebrafish ERs. Limited proteolysis assays of in vitro translated zebrafish ERa, ERb-A and ERb-B with E2 as
ligand (A,C,E, respectively) and genistein as ligand (B,D,F, respectively). For each proteolysis panel, the first line represents the undigested protein, line
2 shows digestion of the receptor in the absence of ligand, lines 3 to 8 show digestion of the receptor in the presence of 10 fold increased
concentrations of E2 and genistein from 1028 M to 1023 M.
doi:10.1371/journal.pone.0004935.g004
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absence or presence of ICI (1 mM). The Luc activity was then
measured from pooled pairs of juveniles (Table 2) and was at
background levels in non-treated fishes (not shown). In presence of
1 mM E2, we observed a very strong (6206) induction of Luc
activity, whereas, as expected, ICI 182,780 does not induce any
activation and completely abolishes E2 induced activity. In
presence of 2,5 mM genistein, Luc activity is well induced (215
fold), but no induction is detected when we co-treated with 1 mM
of ICI (Table 2) clearly suggesting that this effect is ER-dependent.
We conclude from these results that genistein can activate the
estrogen pathway in vivo through a direct binding to the estrogen
receptors.
Genistein regulates aromatase-B expression in an
estrogen dependent manner
Given that the estrogenic effect of genistein in vivo described
above was obtained in larvae, we studied if genistein can elicit a
transcriptional response on an endogenous gene with embryonic
expression. We thus studied if genistein was able to induce the
expression of the aromatase (CYP19) genes, classical ER target genes
in vivo (reviewed in [57]). E2 production via aromatase is crucial for
development, growth and differentiation of the brain and has been
well characterized in zebrafish [58]. Indeed, the teleost fish brain is
characterized by an important aromatase activity due to the
expression of a brain-specific aromatase-B gene (aro-B) [59]. The
expression of this gene is upregulated by E2 and recent studies
indicate that the aro-B gene can be used as a sensitive marker of the
effects of xenoestrogens on the central nervous system during
embryogenesis [60] and in zebrafish juveniles [61]. Whole mount
in situ hybridizations were performed on 48 hpf embryos using
aromatase-A and -B probes. We were not able to detect aromatase-A
transcripts by in situ during embryogenesis but we could detect
embryonic expression of this gene by RT-PCR (data not shown).
In contrast, we observed a faint signal with the aro-B probe in the
mediobasal hypothalamus (MBH) (arrow Figure 7A). Therefore,
we focused on the aromatase-B expression at 48 hpf, in order to
compare the effects in terms of gene expression in response to
genistein and E2 treatments.
In 48 hpf embryos, after E2 treatment (1 mM) from 5 to
48 hpf, aromatase-B transcripts were detected in the olfactory area
(OA) (white arrow), the telencephalon (TEL) (white arrowhead),
the preoptic area (POA) (black arrowhead) and strongly in the
Figure 5. Genistein activates the three zebrafish ERs. In transient transfection (A–E), genistein is able to modulate the transcriptional activity of
the three zebrafish estrogen receptors in a less effective way than their natural ligand E2. We did not observe a difference of genistein-induced
activity between zebrafish ERa and ERb as there is for human ERa and ERb (compare A with C).
doi:10.1371/journal.pone.0004935.g005
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MBH (black arrow) (Figure 7B) in accordance with recently
published data [62]. In embryos treated with genistein (2,5 mM),
we observe clear staining in the PAO and in the MBH
(Figure 7C, arrowhead and arrow, respectively), but no signal
can be detected in the telencephalon or in the olfactory area.
Interestingly, this induced expression pattern for aro-B resembles
what is observed when a low dose of E2 is applied to the
developing embryo. Indeed, when treated with 1 nM of E2
aromatase-B transcripts are detected in the POA and the MBH
(Figure 7D) in a pattern similar to the one observed when the
embryos are exposed to 2.5 mM of genistein (compare Figure 7C
and 7D). In 1 nM E2 exposed embryos, a faint staining of aro-B
is detected in the POA (white arrowhead, Figure 7D), which is
absent in genistein treated embryos. We therefore conclude that
genistein mimics a weak effect of E2 in term of aromatase-B
expression in the brain.
To confirm that the genistein-induced aro-B expression is ER
dependent, we co-treated embryos with the ER antagonist ICI
182,780 and with genistein. As expected for an ER-mediated
response, ICI treatment alone or combined with genistein totally
abolished aro-B induction in a dose-dependent manner (Figure 7E–
G). Furthermore, co-treatment of zebrafish embryo with E2 and
ICI can severely reduce expression of the aro-B gene (Figure 7H).
These data confirm that genistein can elicit a clear estrogenic
response in vivo in zebrafish embryos. This is in accordance with
the observation that these embryos express the estrogen receptors
Figure 6. (A) Alignment of a part of the ligand binding domain of several vertebrate ERs. The two main amino acids involved in the binding of
genistein are underlined. Blue for human ERb-like amino acids and pink for human ERa-like amino acids. (B) modelling of the ligand binding pocket of
estrogen receptors in presence of genistein. The sequences used for the modelling were from human (hERa and hERb) or from zebrafish (zfERa,
zfERb-A, zfERb-B). The a-type amino acids are boxed in blue whereas the b-type amino acids are boxed in red. The non variable amino acids are not
boxed. Numbering refers to each receptor.
doi:10.1371/journal.pone.0004935.g006
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as well as several transcriptional coactivators from early develop-
mental stages through larval stages [48,52].
Discussion
In this paper, we report that genistein induces two distinct
responses in zebrafish embryos: (i) it specifically induces apoptosis
during early embryogenesis in an estrogen receptor-independent
manner. Importantly, we observed that this genistein-induced
apoptosis is linked to a specific developmental process since
exposure of genistein later in development does not lead to the
same effect; (ii) it induces a clear estrogenic response in vivo by
regulating the aromatase-B expression, a classical ER-target gene in
vivo in an ER-dependent manner. In addition, we show that
Figure 7. Genistein regulates aromatase-B expression in the brain in an estrogen receptor-dependent manner. In toto in situ
hybridization showing the expression of aromatase-B in the zebrafish brain at 48 hpf. (As) Control embryo with weak expression detected in
mediobasal hypothalamus (MBH) (arrowheads). (Bs) After genistein exposure, expression is observed in MBH (arrowheads) and in the preoptic area
(POA) (arrows). ER antagonists, like ICI, do not induce aromatase-B expression (Cs). The weak staining observed in the MBH in controls is no longer
detected in ICI-treated embryos. Cotreatment of genistein and ICI abolishes aromatase-B expression (Ds), but a low dose of ICI does not totally block
genistein-induced aromatase-B expression (compare Ds with Es). E2 at high concentrations induces expression of aromatase-B in the MBH
(arrowhead), POA (arrow) and in the telencephalon (Tel). When a lower concentration of E2 (1 nM) is used, expression is no longer detected in the
anterior brain (Tel) but remains in the MBH (arrowhead) and POA (arrow) as after genistein exposure (compare Gs and Bs). As for genistein,
cotreatment of ICI with low concentrations of E2 strongly reduces aromatase-B expression (Hs).
doi:10.1371/journal.pone.0004935.g007
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genistein is a potent zebrafish ER agonist both in vitro and in vivo.
Our results thus highlight the multiplicity of possible actions of
phytoestrogens, such as genistein. This suggests that the use of
standardized endpoints to study the effect of a given compound,
even when this compound has well known targets, may carry the
risk of overlooking interesting effects of this compound.
Genistein exposure induces apoptosis during zebrafish
embryogenesis
Few studies have dealt with the effect induced by an isoflavone
like genistein during embryonic development. Therefore, little is
known about the developmental effects induced by exposure of
this compound during vertebrate embryonic development. In
quail embryos, for example, administration of genistein after three
days of incubation leads to a decrease of copulatory behavior at
puberty [63], but the possible effects during embryogenesis have
not been assessed. The zebrafish is an excellent model for such a
study, given its transparency and the fact that its development is
well known. Using the zebrafish embryo, we showed a clear in vivo
developmental effect induced by genistein: a strong apoptosis
mainly located in the hindbrain and the anterior spinal cord.
Interestingly, genistein also induces apoptosis in the brain, when
adult Sprague-Dawley rats where given up to 20 mg/day genistein
[64]. The same study has shown that in rat brain tissue
homogenates as well as in primary cultures of rat cortical neurons
high concentrations of genistein decrease the expression of the
32 kDA caspase 3 precursor and increase the levels of the cleaved
active form of this caspase that is well known to be instrumental in
the apoptosis pathway. One putative scenario for genistein
induction of apoptosis in the CNS could therefore be by
stimulating the cleavage of the Caspase 3 protein. It therefore
would be of interest to monitor the balance between cleaved and
uncleaved Caspase 3 protein in the developing brain of zebrafish
embryos exposed to genistein. It has to be noted, however, that
genistein can induce apoptosis by modifying either the expression
level or the phosphorylation status of several actors of the
apoptotic cascade as has recently been shown using human
neuroblastoma cells [65]. These data suggest that the precise
manner, by which genistein induces apoptosis remains to be
resolved.
Recently another study has suggested that genistein can induce
early developmental defects. Indeed, using mouse blastocysts,
Chan et al., have shown that genistein treatment induces
apoptosis, decreases cell number and delays early post implanta-
tion development [66]. Even more interestingly these authors also
reported that genistein treatment increases early-stage death in vitro
suggesting that it negatively affects early mouse embryonic
development in vivo by inducing cell apoptosis and by inhibiting
cell proliferation [66]. Interestingly in this study, treatment with
daidzein, another soy isoflavone, does not have an effect similar to
the one we observe in zebrafish embryos.
All these data clearly suggest a need for more studies on the
apoptotic effect of genistein and related isoflavonoids during
development as well as in adults. It will be particularly interesting
to address, whether the reported chemopreventive effect of
genistein on breast cancer and other malignancies can be linked
to its apoptotic effect. It is important to note that the level of
genistein needed in our study to obtain an effect (2.5 mM) is only
10 fold higher to the levels reported in human plasma (up to
300 nM) [67].
The apoptotic effect of genistein is ERs independent
It has been demonstrated that isoflavones can also exert
biological effects independent of their phytoestrogenic activities
[68]. In the present study we report an effect of genistein in
inducing apoptosis that is apparently independent of the estrogen
receptors. Indeed, estrogen exposure does not have an effect that is
similar to genistein treatments and we did not observe a block of
genistein-induced apoptosis when we cotreated fish with classical
ER antagonists (either ICI 182,780 or tamoxifen), and genistein.
Given that ICI 182,780 will occupy the ERs expressed during
early zebrafish embryogenesis, its presence in addition to genistein
should lead to a decrease of genistein action, that is a decrease in
the number of apoptotic cells. This is exactly the effect we observe
when clear estrogenic actions of genistein are studied that is the
luciferase activity in the ERE-Luc reporter transgenic fish and the
aromatase-B expression in zebrafish brain. In contrast, suing several
ratios between ICI 182,780 and genistein we did not see any
inhibitory (nor synergistic) effects between both compounds. All
these data thus suggest that genistein induces apoptosis through
another target than estrogen receptors.
Two main alternative targets for genistein have been described.
It has been shown, two decades ago, that genistein is a direct
potent inhibitor of tyrosine-specific tyrosine kinases, such as EGF
receptor or the proto-oncogenes src and fes [27]. More recently
genistein was shown to bind to transthyretin and to have a
beneficial effect as an inhibitor of transthyretin amyloidosis [26].
Several studies have also reported that both tyrosine-specific
tyrosine kinase of the EGF receptor and transthyretin play a role
in apoptosis. It is possible that the high number of apoptotic cells
observed in zebrafish embryos after exposure to genistein might be
due to a deregulation of at least one of these genes.
Recently the genes responding in male zebrafish liver to the
exposure to 17 b -estradiol, and genistein were identified through a
microarray analysis [69]. Interestingly these data reveal that fish
exposed to 17 b-estradiol and genistein have similarities in their
gene expression patterns and genistein was found to regulate
several genes involved in cell cycle-regulation. These observations
are fully consistent with estrogen receptor-independent and -
dependent effects of genistein that we describe here through
developmental analysis.
No ERa/b selectivity in fish for genistein
In this paper, we demonstrate that genistein binds and activates
the three zebrafish ERs (Figure 4 and 5). Moreover we show that
despite to what is happening in humans, where there is a
considerably weaker affinity of genistein for ERa [13,18,19,23,54],
there is no major difference in the binding and transactivation
capacity of the three different zebrafish ERs (Figure 5C, D).
According to Manas et al. 2004, two key amino acids involved in
genistein binding differ between human ERa and making the ERb
more selective to genistein [23]. We observed that one of these
amino acids (the position homologous to Met 336 in human ERb)
is mutated in fish ERbs making them similar to ERa (Figure 6A).
For the second amino acid, the a/b difference found in the human
receptors is maintained in fish: Met for ERa and Ile for ERb
(Figure 6A). Therefore, a single amino acid difference is
apparently not sufficient to have a/b difference of affinity for
genistein binding. In addition, comparative analysis of the
interaction between genistein and the residues that line the ligand
binding pocket clearly indicates that the substitution of human
ERb Met 336 by Leu (at position 354 and 369 in zebrafish
ERb2A and ERb2B, respectively) is likely to decrease the affinity
of zebrafish ERbs for genistein as compared to human ERb
(Figure 6B). This observation is in agreement with the measured
EC5O in reporter assay (Figure 5) that show a one log increase for
zebrafish ERbs as compared to human ERb. Interestingly, frogs
display the same pattern of amino acids as fish for these two
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particular amino acids and differences to this trend are only
observed at the level of the amniotes (Figure 6A). These data
suggest that variations in the ligand binding pocket may have
occurred during vertebrate evolution that might explain species-
specific patterns in the effects elicited by a given compound. A
similar example, linked to a pharmacological difference in the
binding of synthetic compounds, has recently been observed for
retinoic acid receptors in fish and Xenopus versus amniotes [53]. In
the case of ERs this species difference is interesting and may have
important functional consequences in the precise pharmacology of
the receptors in terms of the response to natural compounds, such
as phytoestrogens, and synthetic ones, such as endocrine
disruptors. Clearly our data prompt for a careful analysis of the
transcriptional patterns generated by a wide variety of compounds
in fish and mammalian ERs.
Materials and Methods
Fish stocks
Zebrafish of the Konstanz wild type strain and the AB/TU wild
type strain were reared at 28.5uC and staged as previously described
[45]. No differences in the effects of genistein on these two strains
were observed. The development of endogenous pigments was
inhibited by exposing embryos to 1-phenyl-2-thiourea (PTU) at a
final concentration of 0.2 mM. We specifically checked that this
PTU treatment does not have any effect on apoptosis in vivo.
Treatment of zebrafish embryos
Embryos were incubated with various concentrations of genistein
(Sigma) (from 0.1 mM to 17.5 mM), 17b-estradiol (E2) (from 1 nM to
0.1 mM), ICI 182,780 (from 0.5 mM to 50 mM), genistin (Calbio-
chem), apigenin (Sigma) and daidzein (Sigma) at 10 mM diluted in
embryomedium from a 1021 M stock solution in ethanol from 5 hpf
onwards unless specified otherwise. As controls, wild-type embryos
were treated with equivalent amount of ethanol.
Whole-mount in situ hybridization and photography
Whole-mount in situ hybridizations were performed as previ-
ously described [70]. Images were processed using Zeiss
Stereomicroscope LUMAR with epifluorescence and Adobe
Photoshop software
Cloning of the aromatase-B probe
Zebrafish aromatase-B probe [62] was amplified by PCR using
the following primers (forward: 59-GACGGATCCAGCATGTG-
fGTAAAGGATGCGG-39; reverse: 59-CCGCTCGAGGAGAC-
CTGGACCTGTAAGAG-39) and cloned into the pCRII-TOPO
vector (Invitrogen).
Acridine orange staining
Live embryos were stained for apoptotic cells with the vital dye
acridine orange (Sigma) that permeates acidic lysosomal vesicles
and becomes fluorescent, thus marking cells dying by apoptosis.
The stock solution (5 mg/ml in egg water, 3006) was diluted to
16concentration and dechorionated embryos were bathed in this
solution for 20 minutes in the dark. Embryos were washed in
embryo medium and analyzed under a fluorescence microscope.
40 embryos per points were manually counted in blind
experiments for the quantitative data (see Sup. Figure 2)
TUNEL assays
Embryos were fixed in 4% paraformaldehyde in PBS for
4 hours at room temperature, washed twice in PBS-Tween 0.1%
and stored in methanol at 220uC, following progressive
dehydratation. Assays were performed using in situ cell death
detection kit (POD, Roche) as described by the manufacturers.
Cell death was detected either using the peroxidase reaction or by
directly detecting the incorporated FITC-labeled nucleotides using
a fluorescent microscope [47].
Transient transfections
HeLa cells were maintained at 37uC in 5% CO2 in Dulbecco’s
modified Eagle medium (DMEM) F12 with phenol red, supple-
mented with 5% FCS and 1% antibiotic (penicillin/streptomycin).
Transfections were performed with Jet-PEI according to the
manufacturer’s recommendations (Ozyme, Saint Quentin-en-
yvelines, France) and using 0.1 mg of the pSG5 expression vector
for the ERa, ERb-A and ERb-B, 0.4 mg of the estrogen-
dependent luciferase reporter construct (ERE-b-globin-Luc SV-
Neo) and 0.2 mg of the internal reference reporter plasmid per well
(CMV-Gal). After overnight incubation, the medium was removed
and the cells were placed into fresh medium supplemented with
control vehicle or compounds. After 24 h, cells were harvested and
assayed for luciferase and b-galactosidase activities as previously
described [71].
Luciferase assay in transiently transfected cells
Cell lysates were prepared as recommended by Promega.
Briefly, cells were washed twice with 1 ml of PBS and lysed with
0,4 ml of lysis buffer [25 mM Tris-phosphate (pH 7,8), 2 mM
EDTA, 10% glycerol and 1% Triton X-100] for 10 min. Cell
lysate (100 ml) was transferred in a 96 well plate white opaque
tissue culture plates (Greiner Cellstar, D. Dutscher) and main-
tained in 6% DCC-FCS. Genistein was added 8 hours later and
cells incubated with compound for 16 hours. Luminescence was
detected after injection of 100 ml of luciferase detection buffer
[2 mM Tricine (pH 7,8), 1.07 mM (MgCO3) 4Mg(OH)2,
2.67 mM MgSO4, 0.2 mM EDTA, 0.53 mM ATP, 0.27 mM
CoA and 0.48 mM luciferin] and the 96-well plate was then
introduced into a microplate luminometer (Microbeta) and intact
living cell luminescence measured for two seconds. Arbitrary units
in transient transfection experiments represent a ratio of
luminescence to b-galactosidase activity used as transfection
control.
Limited proteolysis assay
The assays were performed as described in [52]. Genistein was
incubated with the protein at different concentrations (from
10 nM to 1 mM). After incubation SDS-PAGE was performed
using a 12% gel. Electrophoresis was carried out using a BioRad
gel apparatus at 170 V for 50 minutes and the polyacrylamide gel
was visualized by autoradiography.
In vivo luciferase assay
We used the transgenic ERE-Luc fish line described by [54,55].
Male fish with a weight of 300 mg (three to six months old) were
exposed for 48 hours to one ligand or to a mixture of two ligands
in glass aquaria (E2, ICI 182,780 and/or genistein). Ligands were
dissolved in ethanol (or in DMSO) at concentrations of 1021 M or
1023 M and titrated to final concentrations not exceeding a
solvent concentration of 0.01%. Single fish were anaesthetized
(0.6 mM Tricain methanesulfonate) and transferred to an
Eppendorf tube. Then, 135 ml of ice cold Triton-lysis buffer
(1% triton-X-100; 15 mMMgSO4; 4 mM EGTA pH 7.0; 35 mM
glycylglycine pH 7.8; 1 mM DTT) was added to each tube
following homogenization using a micropestle. After centrifugation
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the supernatant was transferred to a new tube and extracts were
measured in luminometric reporter gene assays carried out in
duplicates in a Microplate Luminometer (Anthos). Light units
from extracts of ligand-exposed fish and from non-exposed fish
were used to calculate fold inductions.
Bioinformatics
Partial sequences of estrogen receptor genes from various
vertebrates were aligned using the ClustalW software available on
the web (http://bioinfo.hku.hk/services/analyseq/cgi-bin/clustal-
w_in.pl).
Construction of 3D models
3D structures of ERa, ERb-A and ERb-B of Danio rerio were
modelled on the human ERa (1X7R) and ERb (1X7J) using the
web-based Swiss-Model server. The figure was prepared using the
Swiss-PDB Viewer software (v3.9).
Supporting Information
Figure S1 Detection of apoptosis in genistein treated fishes using
TUNEL assays, a direct method for the presence of fragmented
DNA (Lawry 2004). Fishes were treated at 5 hpf and labeled at
24 hpf with the indicated concentration of genistein. We observe a
dose-dependent activation of apoptosis starting at 0.5 mM.
Found at: doi:10.1371/journal.pone.0004935.s001 (0.79 MB TIF)
Figure S2 Genistein-induced apoptosis is estrogen receptor
independent. Fish were treated at 5 hpf by the various compounds
at the indicated concentration and apoptosis was monitored by
acridine orange staining at 27 hpf. The number of apoptotic cell
per fish was counted. Batch of 20 fishes were treated by the
indicated compounds and the number of apoptotic cells per fish
was counted after acridine orange staining. The experiment was
done twice, thus a total of 40 fishes per point was analyzed. (Upper
panel) Effect of ER agonists and antagonists on genistein induced
apoptosis. G: Genistein; E2: 17b-estradiol; ICI: ICI 182,780;
Tamox: Tamoxifen. It is interesting to note that neither E2 nor
ICI or Tamoxifen alter the magnitude of the apoptotic effect
elicited by genistein. (Lower panel) The apoptotic effect elicited by
ICI treatment is reverted by a cotreatment with E2 suggesting it is
ER-mediated. The statistical analysis shows the result of a t-test
with a Bonferroni correction (***: p value,0.005). In the upper
panel, we compare the number of apoptotic cells in each indicated
column with the number of apoptotic cells present after a
treatment at 5 mM genistein.
Found at: doi:10.1371/journal.pone.0004935.s002 (0.28 MB TIF)
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